Medpharm Limited
Registered name: MEDPHARM LIMITED
Part of Medpharm Holdco Limited groupMedpharm Limited made £9m revenue and a £26.2m loss in the year to 31 Dec 2024.
Medpharm Limited’s revenue fell 20% to £9m in the year to 31 Dec 2024, with a loss of £26.2m and 78 employees. The company is classified under “research and experimental development on biotechnology” and is based in Guildford; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Guildford, South East
- Age
- 27 yrs · since 1999
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £18.7m | £11.3m | £9m |
| Cost of sales | £17.6m | £13.2m | £9.9m |
| Gross profit | £1.1m | −£1.9m | −£837k |
| Operating profit | −£5.4m | −£6.9m | −£5.1m |
| Profit before tax | −£5.4m | −£6.9m | −£26.1m |
| Profit after tax | −£4.9m | −£6.9m | −£26.2m |
| Profit (best available) | −£4.9m | −£6.9m | −£26.2m |
| Staff costs | £5.1m | £4.2m | £3.5m |
| Employees (average) | 115 | 94 | 78 |
| Ratios | |||
| Profit margin | −26.4% | −60.8% | −289.8% |
| Gross margin | 5.7% | −16.5% | −9.3% |
| Revenue per employee | £162k | £120k | £116k |
| Profit per employee | −£42.9k | −£73k | −£336k |
| Growth (year on year) | |||
| Revenue growth | — | ▼39.5% | ▼20% |
| Headcount growth | — | ▼18.3% | ▼17% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £977k | £576k | £217k |
| Net assets | £609k | −£6.3m | −£32.5m |
| Fixed assets | £3.2m | £3m | £2.3m |
| Current assets | £7m | £4.7m | £6.7m |
| Debtors | £2.5m | £1.4m | £1.5m |
| Deferred income | £3m | £2.1m | £2m |
| Source | FullAccounts · bulk data Apr 2025 | FullAccounts · bulk data Apr 2025 | FullAccounts · bulk data Jul 2026 |
How the business works
- Profit margin
- −289.8%
- Profit ÷ revenue.
- Gross margin
- −9.3%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £116k
- Revenue ÷ average employees.
- Profit per employee
- −£336k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 25.5%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 22%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 16.4%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£32.5m
- Cash at bank
- ▼62%
- Now £217k
- Headcount
- ▼17%
- Now 78
- Deferred income
- ▼6%
- Now £2m
- Fixed assets
- ▼22%
- Now £2.3m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Ownership chain
- Medpharm Holdco Limitedultimate parent75–100%
- Medpharm Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
- Flatiron Health UK LtdST Albans · Research and experimental development on biotechnology
- Revenue
- £9.5m
- Profit
- £239k
- Staff
- 32
- Biopharma Process Systems LimitedWinchester · Research and experimental development on biotechnology
- Revenue
- £10.1m
- Profit
- £142k
- Staff
- 66
- Askbio UK LtdMidlothian · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £1.8m
- Staff
- 54
- Dna Legal LimitedFrome · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £3.2m
- Staff
- 55
- Clinuvel (UK) LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £6.4m
- Profit
- £81.6k
- Staff
- 46
Sources
Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£26.2m), from the Companies House accounts bulk data published Jul 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.